Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer
Ovarian Cancer
About this trial
This is an interventional treatment trial for Ovarian Cancer
Eligibility Criteria
Inclusion Criteria:
- Able to give written informed consent for participation in the trial;
- Females age 18 to 75 years, inclusive;
- Histologically or cytologically proven ovarian cancer, which has progressed or recurred by CT/MRI confirmation after platinum-based chemotherapy;
- ECOG (Eastern Cooperative Oncology Group) Performance Status 0 - 2;
- Patient is expected to be able to receive both doses of Doxorubicin Hydrochloride Liposome Injection and participate in the trial for at least 56 days.
Urine pregnancy test before dosing of both cycle1 and cycle 2 must be negative (not including postmenopausal or surgically sterile women); Agree to use an approved method of birth control (condom with spermicide, diaphragm or cervical cap with spermicide, or intrauterine device); or patients of non-childbearing potential who are either surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or >1 year postmenopausal with follicle-stimulating hormone in the postmenopausal range;
- 30days or 5 half-lives (whichever is longer) have elapsed from the completion of previous cancer therapy, and patients must have recovered to < Grade 2 or be at new stable baseline from any related toxicities;
- Adequate renal, hepatic and bone marrow function without blood product or hematopoietic growth factor support:
- Able to comply with study requirements in the opinion of the Principal Investigator
Exclusion Criteria:
- Significant allergy, hypersensitivity or idiosyncratic reactions to doxorubicin and/or any related compounds;
- History or presence of cardiac disease rated New York State Heart Association Classification class 2 or greater;
- Uncontrolled cardiac arrhythmia or other findings on screening electrocardiogram (ECG) which could, in the judgment of the Principal Investigator, put the patient at undue risk for participation in the trial;
- LVEF(left ventricular ejection fraction) below 50% or below institutional normal at screening;
- Prior radiation therapy to mediastinum;
- Concomitant use of other cytotoxic or cytostatic drugs or of radiotherapy;
- Active, uncontrolled infection, including opportunistic infection with mycobacteria, cytomegalovirus, toxoplasma, or P. carinii;
- Use of prescription or non-prescription herbal and dietary supplements, within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.
Sites / Locations
- Cancer Institute& Hospital, Chinese Academy of Medical Sciences
- Sun Yat-sen University Cancer Center
- QiLu Hospital of Shandong University
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
doxorubicin hydrochloride liposome(Libaoduo)
doxorubicin hydrochloride liposome
Use the test drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang ),then use the reference drug(doxorubicin hydrochloride liposome,from Sunpharma) after at least 4-weeks.
Use the reference drug(doxorubicin hydrochloride liposome,from Sunpharma),then use the test drug drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang) after at least 4-weeks.